This inventor holds 2 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignee: Albunext, LLC. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Martin Robitaille: Innovator in Pharmaceutical Compositions
Introduction: Martin Robitaille is an accomplished inventor based in Saint-Colomban, Canada. He is currently associated with Kedrion Biopharma Inc., where he focuses on developing innovative pharmaceutical solutions. Despite having no granted patents to his name, his contributions to the field of drug delivery systems are noteworthy.
Latest Patent Applications: Martin Robitaille has been involved in several significant patent applications. One of his latest applications is for "Orally Available Albenatide," which presents orally administrable pharmaceutical compositions comprising an incretin or its analogs. These formulations utilize a self-emulsifying drug delivery system (SEDDS) that protects the drug from the harsh conditions of the upper gastrointestinal tract while ensuring effective release and absorption in the lower gastrointestinal tract. Another notable application is for "Albumin Bound Macromolecule Tri-Agonist Activating GLP-1/GIP/Glucagon Receptors." This composition features a GPCR agonist fusion protein that is covalently coupled to albumin, enhancing the therapeutic efficacy while minimizing adverse effects commonly associated with unbound agonists.
Conclusion: Martin Robitaille's work in pharmaceutical compositions showcases his innovative approach to drug delivery systems. His latest patent applications reflect his commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile